Health & Environmental Research Online (HERO)


Print Feedback Export to File
3460580 
Journal Article 
Identification of biomarkers of exposure to FTOHs and PAPs in humans using a targeted and nontargeted analysis approach 
Dagnino, S; Strynar, MJ; Mcmahen, RL; Lau, CS; Ball, C; Garantziotis, S; Webster, TF; Mcclean, MD; Lindstrom, AB 
2016 
Environmental Science & Technology
ISSN: 0013-936X
EISSN: 1520-5851 
AMER CHEMICAL SOC 
WASHINGTON 
50 
18 
10216-10225 
English 
is supplemented by 3980918 : Supplemental materials
Although historic perfluorinated compounds are currently under scrutiny and growing regulatory control in the world, little is known about human exposure to other polyfluorinated compounds presently in use. Fluorotelomer alcohols (FTOHs) and polyfluoroalkyl phosphate esters (PAPs) are known to degrade to terminal perfluorinated acids and toxic reactive intermediates through metabolic pathways. Therefore, it is important to characterize their human exposure by the identification of unique biomarkers. With the use of liquid chromatography-mass spectrometry-time-of-flight analysis (LC-MS-TOF), we developed a workflow for the identification of metabolites for the 8:2 FTOH and 8:2 diPAP. Analysis of serum and urine of dosed rats indicated the 8:2 FTOH-sulfate and the 8:2 diPAP as potential biomarkers. These compounds, as well as 25 other fluorinated compounds and metabolites, were analyzed in human serum and urine samples from the general population (n = 100) and office workers (n = 30). The 8:2 FTOH-sulfate was measured for the first time in human samples in 5 to 10% of the serum samples, ranging from 50 to 80 pg/mL. The 8:2 diPAP was measured in 58% of the samples, ranging from 100 to 800 pg/mL. This study indicates the FTOH-sulfate conjugate as a biomarker of exposure to FTOHs and PAPs in humans. 
Phosphate esters; Mass spectrometry; Chromatography; Metabolites; Rodents; Biomarkers; 2016) 
PFAS
• 6:2/8:2 diPAP
     Literature Search
          Pubmed
          WOS
     Screening Results
          Excluded/Not on Topic
• 6:2 diPAP
     Literature Search
          WOS
     Screening Results
          Excluded/Not on Topic
• 8:2 diPAP
     Literature Search
          Pubmed
          WOS
     Screening Results
          Excluded/Not on Topic
• Additional PFAS (formerly XAgency)
     Literature Search November 2019
          Web of Science
     Screened Studies
          Supplemental
     8:2 Fluorotelomer phosphate diester
• FtOH 8:2
     Literature Search
          Pubmed
          WOS
     Screening Results
          Toxicokinetic studies
               ADME
• ^Per- and Polyfluoroalkyl Substances (PFAS)
     PFOA (335-67-1) and PFOS (1763-23-1)
          Literature Search – Adverse outcome pathway (2015-present)
               WOS
     FtOH 8:2 (678-39-7)
          Literature Search
               Pubmed
               WOS
     6:2 diPAP (57677-95-9)
          Literature Search
               WOS
     8:2 diPAP (678-41-1)
          Literature Search
               Pubmed
               WOS
     6:2/8:2 diPAP (943913-15-3)
          Literature Search
               Pubmed
               WOS
• PFAS 150
     Literature Search Update December 2020
          PubMed
          WOS
     Literature Search August 2019
          PubMed
          Web of Science
     Screened Studies
          Supplemental
     8:2 Fluorotelomer alcohol
     Perfluorinated compounds
     Perfluorooctanoic acid
• PFOA (335-67-1) and PFOS (1763-23-1)
     Literature Search – Adverse outcome pathway (2015-present)
          WOS
     Screening Results
          Excluded/Not on Topic
     Literature Search Update (2013-2019)
          WOS